Drug Quality Focus On Asia, OTCs Supported By New US FDA Data

14 Jun 2020

OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.

Compass needle pointing the blue text. Blue and black tones with blur effect and focus on the main word. Concept for quality assurance management. — drug quality suffered over the counter and across the sea

The US Food and Drug Administration's scrutiny of consumer drug quality and Asian manufacturing facilities is likely to intensify, given the chief findings of the agency's second annual “state of pharmaceutical quality” report.

Many of the new report’s findings mirror those of the agency’s first report, issued in May 2019. (Also see "